Dong, Li
Shi, Xu Han
Kang, Yi Kun
Wei, Wen Bin
Wang, Ya Xing
Jonas, Jost B.
Funding for this research was provided by:
Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20150201)
China National Funds for Distinguished Young Scientists (81570891;81272981)
Beijing Natural Science Foundation (7151003)
Guangzhou Municipal Health and Family Planning Commission (2014-2-003)
Study on individual diagnosis and therapy strategy for malignant uveal melanoma (2016-1-2051)
Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201307)
Science & Technology Project of Beijing Municipal Science & Technology Commission (Z151100001615052)
Article History
Received: 31 January 2019
Accepted: 22 April 2019
First Online: 3 May 2019
Ethics approval and consent to participate
: The Ethics Committee of the Beijing Tongren Hospital study approved the study, and the ARVO Statement for the use of animals in ophthalmic and vision research was taken into account.
: Not applicable
: Jost B. Jonas: Patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; European Patent Number: 3070101).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.